Q-omics provides the consensus-scored TRIM52 profile across patient tissues and cancer cell-line models. TRIM52 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TRIM52 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TRIM52 RNA expression shows 20,874 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where TRIM52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM52 survival associations across molecular data types. TRIM52 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM52 RNA expression–survival associations across cancer types. High TRIM52 expression shows unfavorable associations in UVM, LIHC, LGG, MESO and COAD, but favorable associations in BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify UVM as the clearest survival context for TRIM52 RNA expression.
This table summarizes TRIM52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM52 shows lower tumor expression in THCA and LUSC and higher tumor expression in KIRC, LIHC, CHOL and COAD. The KIRC box plot shows higher TRIM52 RNA expression in tumor versus normal tissue (log2 FC = +0.590, t-test p < 0.001).
This table shows molecular features associated with TRIM52 in patient tissues and cancer cell lines. In patient samples, TRIM52 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM52 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
